CLINICAL NUCLEAR MEDICINE, vol.47, no.3, 2022 (SCI-Expanded)
A 56-year-old man underwent 68Ga-DOTATATE PET/CT with suspicion of a pancreatic neuroendocrine tumor. However, in this imaging, a mass with 68Ga-DOTATATE uptake was observed not in pancreas but in the duodenojejunal junction. Abdominal tomography confirmed that the heterogeneously enhanced mass was originated from duodenum. The patient was operated, and the histopathology result was evaluated as low-risk gastrointestinal stromal tumor. Although there was low or no specific binding to gastrointestinal stromal tumor cells for all 68Ga-labeled DOTA peptides, uptake of 68Ga-DOTATATE was observed incidentally in this case.